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Concurrent Administration of Sirolimus and Voriconazole:
A Pilot Study Assessing Safety and Approaches to
Appropriate Management
Dorothy Surowiec, Pharm.D., Daryl D. DePestel, Pharm.D., and Peggy L. Carver, Pharm.D., FCCP
Study Objectives. To assess the use and safety of concurrent administration
of voriconazole and sirolimus—which is contraindicated—and to
determine approaches for appropriately managing patients who receive
both drugs.
Design. Retrospective medical record review.
Setting. University-affiliated medical center.
Patients. Thirty-one cases in 23 inpatients who received at least one dose of
voriconazole and sirolimus concomitantly within a 24-hour period.
Measurements and Main Results.  Data on sirolimus and voriconazole
indications, doses, routes, frequencies, and administration times; number
of days of coadministration; and sirolimus dosage adjustments were
collected.  In addition, data on laboratory values, adverse events, sirolimus
concentrations, and concomitant drugs, including cytochrome P450 (CYP)
3A isoenzyme and P-glycoprotein inhibitors and inducers, were collected
for 7 days before, during, and for 14 days after coadministration.  No cases
of elevated sirolimus concentrations (> 20 mg/ml) occurred in patients
stabilized with voriconazole before starting low-dose sirolimus 0.5–1
mg/day, or in those stabilized with sirolimus 0.5–2 mg/day who had
baseline sirolimus concentrations of 12 ng/ml or lower and whose sirolimus
dose was decreased by 50% before the addition of voriconazole.  In
contrast, elevated sirolimus concentrations were experienced in patients
receiving sirolimus doses of 4 mg/day or higher who had sirolimus
concentrations of 12 ng/ml or higher and whose sirolimus dose was not
decreased before addition of voriconazole.  In a patient who received
sirolimus with itraconazole, a strong CYP3A isoenzyme inhibitor, one case
of only a minimal increase in the sirolimus concentration occurred after the
addition of voriconazole.
Conclusions.  Sirolimus and voriconazole can be safely coadministered as long
as consideration is given to which agent the patient receives first, the
sirolimus dosage, sirolimus concentrations, and concurrent disease states
and CYP3A isoenzyme inhibitors.  Sirolimus concentrations should be
closely and routinely monitored before, during, and after coadministration
of voriconazole and other CYP3A isoenzyme inhibitors.  Based on the results
of this pilot study, a protocol on the management of this drug combination
will be implemented and prospectively evaluated for efficacy and safety.
Key Words: voriconazole, sirolimus, transplantation, aspergillosis, drug
interaction.
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The incidence of invasive fungal infections has
increased dramatically in the United States:
among infectious diseases–related deaths, those
due to invasive fungal infections increased from
the tenth most common in 1980 to the seventh
most common in 1997.1 In particular, patients
who have undergone solid organ or hematopoietic
stem cell transplantation are susceptible to
invasive fungal infections because of multiple
risk factors, some of which include treatment
with immunosuppressive and/or broad-spectrum
antimicrobial agents, graft-versus-host disease
(GVHD), neutropenia, or the presence of central
venous catheters.2, 3
Invasive fungal infections in transplant
recipients are frequently caused by Aspergillus
species.  Voriconazole, a second-generation
triazole antifungal, is often used for prophylaxis
or treatment of these infections in transplant
recipients as it provides coverage for Candida and
Aspergillus species.2, 4 Voriconazole was shown to
be efficacious in noncomparative studies as
primary or salvage therapy for invasive fungal
infections.5–7 Furthermore, it has emerged as the
therapy of choice for these infections caused by
Aspergillus species, as it demonstrated higher
response rates and improved survival compared
with amphotericin B in the treatment of invasive
aspergillosis.8
Voriconazole inhibits cytochrome P450
(CYP)–dependent 14a-lanosterol demethylase,
the CYP enzyme responsible for the synthesis of
cell membrane ergosterol in fungi.  It is both a
substrate and an inhibitor of human hepatic
CYP2C19, CYP2C9, and CYP3A isoenzymes,
increasing the potential for drug interactions
with other agents that are substrates of these
enzymes, including sirolimus, an antirejection
agent used in transplant recipients.9, 10 Voriconazole
drug interactions are dose dependent and are
often difficult to predict and manage, in part due
to its unpredictable, nonlinear pharmacokinetics
and the variability in its concentrations due to
genetic polymorphisms of CYP2C19.10
Sirolimus is an immunosuppressive agent that
prevents T-lymphocyte activation and prolifer-
ation and antibody production.  Unlike tacrolimus
and cyclosporine, it does not inhibit calcineurin
activity but works by inhibiting the activation of
the mammalian target of rapamycin.  It is
indicated for the prophylaxis of organ rejection
in patients receiving kidney transplants; however,
it has also been used for the prevention or
treatment of rejection in other solid organ
transplant recipients and GVHD in hematopoietic
stem cell transplant recipients.11–15
Concomitant use of voriconazole with sirolimus
is contraindicated by the manufacturer9 because
voriconazole inhibits CYP3A isoenzymes, the
enzymes responsible for metabolizing sirolimus,
resulting in greater susceptibility to dose-related
adverse effects of sirolimus, including renal
dysfunction, leukopenia, thrombocytopenia, and
anemia.11 Repeated doses of oral voriconazole
400 mg every 12 hours for 1 day, then 200 mg
every 12 hours for 8 days administered to 15
healthy young men increased the mean maximum
plasma concentration and area under the plasma
concentration–time curve of a single, oral 2-mg
dose of sirolimus by 7- and 11-fold, respectively.9
Drug interactions between azole antifungals,
such as voriconazole, itraconazole, ketoconazole,
or fluconazole, and immunosuppressive agents,
including sirolimus, have been extensively
reported in the literature.10, 16–19 Although the
onset and duration of voriconazole-mediated
inhibition of CYP3A isoenzymes is unknown, in
studies evaluating other CYP inhibitors,
inhibition occurred immediately after adminis-
tration of the first dose of the CYP inhibitor.20
The duration of CYP3A isoenzyme inhibition
after voriconazole administration is believed to
be affected by its half-life, which is variable and
dose dependent, and by protein binding.9, 20
At our institution, we noted that increasing
numbers of patients were receiving the combination
of voriconazole and sirolimus.  As only very
limited data were available regarding the concurrent
use of these two agents, and we found no data
regarding the management of patients receiving
voriconazole before the start of sirolimus, we
evaluated all patients treated at our institution in
whom both drugs were coadministered.  The
objective of this retrospective study was to assess
the use of concurrent administration of voriconazole
and sirolimus, and to determine approaches for
appropriately managing patients who receive both
drugs.  In addition, the safety of concurrent
administration of voriconazole and sirolimus was
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assessed by determining whether clinicians
prospectively or concurrently adjusted sirolimus
doses, and by evaluating whether patients
experienced increased adverse events due to
elevated sirolimus concentrations after coadmin-
istration with voriconazole.
Methods
In this retrospective study, we reviewed the
medical records of inpatients who were on a
medical service at the University of Michigan
Hospital who received coadministration of
sirolimus and voriconazole between July 1, 2002,
and November 1, 2006.  Institutional review
board approval was obtained, and informed
consent was waived as the study did not involve
any direct patient interventions.  Patients were
included if they were inpatients at the University
of Michigan Hospital and had received at least
one dose of voriconazole and sirolimus
concurrently within a 24-hour period.  Patients
were excluded if their medical records were
unavailable for review or were incomplete.  Each
patient was assigned a case number, and if the
patient was admitted more than one time and
received coadministration of the two drugs, the
original case number followed by a decimal was
used to indicate subsequent admissions (e.g.,
case 2.2 refers to the second admission for the
patient assigned case number 2).
Computerized pharmacy and medical databases
were used to identify inpatients at the hospital
who had drug orders for voriconazole and
sirolimus on the same days.  Medical records and
medication administration records were then
reviewed to confirm the specific doses and
administration times of all drugs.
Demographic data were collected, including
patients’ age, sex, race-ethnicity, type of transplan-
tation, and other comorbidities.  The following
information was collected 7 days before, during,
and 14 days after coadminis-tration of sirolimus
and voriconazole:  indication for sirolimus and
voriconazole based on physician progress notes;
dose, route, frequency, and administration times
for sirolimus and voriconazole; sirolimus
concentrations and time of sample collection;
dose, route, frequency, and administration times
for other concomitant drugs that had potential to
affect the drug interaction; laboratory values; and
adverse effects.  Data on 30-day mortality after
the last day of combination therapy as an inpatient
were also collected.  The definitions of adverse
effects relative to baseline laboratory values are
listed in Table 1.  Data on rash, neurotoxicity, and
death were also assessed.
Sirolimus concentrations were measured by the
liquid chromatography with mass spectrometry
(LCMS) method; a trough concentration of 5–20
ng/ml was considered therapeutic.21–23 In this
study, concentrations greater than 20 ng/ml were
considered elevated based on current clinical
practice in our institution and literature citing
target trough ranges of 12–20 ng/ml (using the
LCMS methodology) after cyclosporine
withdrawal in renal transplant recipients.22–23 At
our institution, sirolimus concentrations are
generally obtained with the morning laboratory
testing in order to minimize collection of blood
samples and to provide a consistent sampling
time (dosing times are also standardized).  In this
study, most (92 [79.3%] of 116 concentrations)
of the patients had random concentrations
obtained.  Troughs were defined as plasma
concentrations obtained within 3 hours before
the next scheduled dose or within 1 hour after
the next scheduled dose if the scheduled dose
was not administered at the correct time.  The
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Table 1.  Definitions of Adverse Effects Relative to Baseline Laboratory Values
Definition
Adverse Effect If Baseline Value Normal If Baseline Value Abnormal
Renal dysfunction Serum creatinine concentration > 1.5 mg/dl 50% ↑ from baseline
Leukopenia White blood cell count < 4.0 x 103/mm3 50% ↓ from baseline
Thrombocytopenia Platelet count < 150 x 103/mm3 25% ↓ from baseline
Anemia Hemoglobin concentration < 12 g/dl (females)
or < 14 g/dl (males) 25% ↓ from baseline
Hematocrit < 35% (females) or < 49% (males)
Dyslipidemia Total cholesterol concentration > 200 mg/dl or Not applicable
triglyceride concentration > 150 mg/dl
Hepatic dysfunction AST or ALT > 3 x upper limit of normala 50% ↑ from baseline
AST = aspartate aminotransferase; ALT = alanine aminotransferase.
aUpper limit of normal for AST is 30 U/L and for ALT is 35 U/L.
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clinical pharmacists on each service interpret the
concentrations based on the timing and estimate
trough concentrations accordingly.
Results
Of 31 patients who had orders for voriconazole
and sirolimus on the same day, there were 43
separate cases.  After reviewing the medication
administration records, 12 cases (in 8 patients)
were excluded because the patients had not
actually received the agents concomitantly within
a 24-hour period.  This left 31 cases (in 23
patients) of coadministration of voriconazole and
sirolimus for inclusion in the study.  In 13
(46.4%) of 28 cases, the patients were discharged
from the hospital with the combination of
sirolimus and voriconazole.  The remaining 3
cases were in patients who died while in the
hospital.
Of the 23 patients, seven had undergone solid
organ transplantation and 16 had received a
hematopoietic stem cell transplant (Table 2).
Coadministration of voriconazole and sirolimus
occurred for a mean of 4.6 ± 4.2 days and ranged
from 1–20 days (Table 3).  Three types of case
scenarios were identified:  in 9 cases (9 patients),
voriconazole was administered before the
addition of sirolimus; in 13 cases (13 patients),
sirolimus was administered before the addition of
voriconazole; and in 9 cases (4 patients), patients
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Table 2.  Demographic Data of the 23 Patients
Characteristic Value
Age at first admission (yrs), 42.7 ± 16.2
mean ± SD
No. (%) of Patients
Male 15 (65)
Race-ethnicity
Caucasian 17 (74)
African-American 3 (13)
Asian 1 (4)
Hispanic 1 (4)
Unknown 1 (4)
Dialysis at baseline 0 (0)
Liver disease 7 (30)
Diabetes mellitus 4 (17)
Autoimmune disease 3 (13)
Solid organ cancer 3 (13)
Solid organ transplant 7 (30)
Lung 5 (22)
Kidney 1 (4)
Liver 1 (4)
Hematologic malignancy 16 (70)
Lymphoma 5 (22)
Leukemia 8 (35)
Other 3 (13)
Hematopoietic stem cell transplant 16 (70)
Table 3.  Summary of Voriconazole and Sirolimus Therapy
in the 31 Cases
Variable Value
No. (%) of Cases
Voriconazole indication
Treatment of a proven or probable
invasive fungal infection 10 (32)
Empiric treatment of an invasive 11 (35)
fungal infection
Primary prophylaxis 5 (16)
Secondary prophylaxis 5 (16)
Sirolimus indication
Treatment of GVHD or rejection 26 (84)
Prophylaxis for GVHD or rejection 5 (16)
Mean ± SD
No. of days of coadministration 4.6 ± 4.2
(range) (1–20)
Weight (kg) 67.1 ± 21.8
Range
Voriconazole dosing
mg/kg/dosea 2.2–6.3
mg/dose 150–600
Sirolimus dosing
mg/kg/dosea 0.007–0.179
mg/dose 0.5–12
GVHD = graft-versus-host disease.
aBased on mean weight of 67.1 kg.
Table 4.  Summary of Coadministration Scenarios and
Sirolimus Concentrations in the 31 Cases
Variable Value
No. (%) of Cases
Scenario
Voriconazole administration 9 (29)
before addition of sirolimus
Sirolimus administration before 13 (42)
addition of voriconazole
Already receiving voriconazole and 9 (29)
sirolimus concurrently on admissiona
Time of sample collection for sirolimus
concentrations
During the admission 30 (97)
Before coadministration 11 (35)
During coadministration 21 (68)
After coadministration 12 (39)
Mean ± SD
Sirolimus concentration from all 12.7 ± 12.0
collections obtained before, during,
and after coadministration (ng/ml)
Range
Sirolimus concentration (ng/ml)
During the admission 2.3–60.0
Before coadministration 2.6–56.0
During coadministration 2.4–40.1
After coadministration 2.3–60.0
aIncludes 5 cases from patient 5, 2 cases from patient 9, and 1 case
each from patients 7 and 14.
CONCURRENT USE OF SIROLIMUS AND VORICONAZOLE  Surowiec et al
were receiving the two agents concurrently on
admission to the hospital.  Overall, sirolimus
concentrations were obtained during the admis-
sion in 30 (97%) of the 31 cases (Table 4).
Voriconazole Administration Before the Addition
of Sirolimus
In this scenario, sirolimus concentrations were
obtained during the period of sirolimus coadmin-
istration with voriconazole in 7 (78%) of the 9
cases (Table 5); however, in 2 patients (cases 11
and 23), no sirolimus concentrations were
obtained during coadministration.  In these 7
cases, the first sirolimus concentration obtained
during coadministration was a mean ± SD of 14.8
± 11.8 ng/ml (range 3.4–36.0 ng/ml) and was
obtained 35.1 ± 24.6 hours (range 6–71 hrs) after
the start of coadministration.  In the 4 cases (1, 3,
7, and 14) in which the initial sirolimus dose was
low (0.5–1 mg/day) and in case 20 in which a 6-
mg loading dose was given, subsequent sirolimus
concentrations were less than 20 ng/ml.  In
contrast, in 2 cases (2 and 8) in which 12- and 4-
mg, respectively, loading doses were given, the
patients experienced elevated (> 20 ng/ml)
sirolimus concentrations of 24.9 and 36.0 ng/ml,
respectively (Table 5).  Figure 1 depicts the
concentrations of sirolimus in case 8:  this patient
was receiving voriconazole before administration
of a 4-mg loading dose of sirolimus; subsequent
sirolimus concentrations were greater than 20
ng/ml.
Sirolimus Administration Before the Addition of
Voriconazole
Sirolimus concentrations were obtained both
before and during coadministration with
voriconazole in 10 of the 13 cases in this scenario
(Table 6); however, in 3 patients (cases 13, 16,
and 19) no sirolimus concentrations were
obtained after the addition of voriconazole.  In
these 10 cases, the mean ± SD baseline sirolimus
concentration was 11.4 ± 8.2 ng/ml (range
3.4–30.8 ng/ml), which was obtained 99.7 ±
114.1 hours (range 2–384 hrs) before the
addition of voriconazole.  The first sirolimus
concentration and its time obtained after addition
of voriconazole were 15.7 ± 12.9 ng/ml (range
2.8–39.6 ng/ml) and 37.7 ± 40.3 hours (range
0.5–141 hrs), respectively.  In 7 cases in which
the patients received sirolimus doses of 0.5–2
mg/day and whose sirolimus concentrations
before adding voriconazole ranged from 3.4–13.2
ng/ml, sirolimus concentrations were less than 20
ng/ml after adding voriconazole (Table 6).
Dramatically elevated sirolimus concentrations
(> 20 ng/ml) occurred in 3 cases in this scenario.
In case 6, the patient received sirolimus 6 mg/day
as an outpatient and had a sirolimus concentration
of 12.5 ng/ml 68 hours before the addition of
voriconazole.  The subsequent sirolimus concen-
tration at hour 102.5 (26 hrs after coadminis-
tration) was 32.7 ng/ml (Figure 2).  In case 12,
the patient received sirolimus 2 mg/day on admis-
sion, but the dose was increased to 4 mg/day on
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Figure 1. Case 8 is an example of dramatically elevated
sirolimus (Siro) concentrations resulting from
administration of a loading dose of sirolimus 4 mg in a
patient receiving voriconazole.  Time 0 is the start of
admission.
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Figure 2. Case 6 is an example of dramatically elevated
sirolimus (Siro) concentrations resulting from voriconazole
(Vori) administration in a patient previously stabilized with
high daily doses of sirolimus (time 0 is 72 hrs before
admission).  Voriconazole was started at a dose of 420 mg
intravenously at hour 76.5 (with time 0 being the time of
admission), with a second 420-mg intravenous dose given at
hour 91.3.  Sirolimus was continued at a dosage of 6 mg/day.
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the second day of admission; 24 hours after the
dose increase the sirolimus concentration was
17.6 ng/ml.  Despite a 50% decrease in the
sirolimus dose after voriconazole was added, a
sirolimus concentration of 27.6 ng/ml was
observed 56 hours after the start of coadminis-
tration.  In case 21, the patient received sirolimus
1 mg every 12 hours in combination with oral
itraconazole 200 mg/day (a strong CYP3A
isoenzyme inhibitor), thus the patient experienced
elevated sirolimus concentrations (30.8–56.0
ng/ml) before coadministration of sirolimus and
voriconazole.  The total daily dose of sirolimus
was reduced by 50% and the sirolimus concen-
tration decreased to 30.8 ng/ml before coadminis-
tration of voriconazole and sirolimus.  Only a
minimal increase in sirolimus concentrations to
39.6 ng/ml was observed with addition of
voriconazole (Figure 3).
Voriconazole and Sirolimus Already Being
Received Concurrently on Admission
In 9 cases (in 4 patients), patients were already
receiving the combination of voriconazole and
sirolimus on admission.  Combination therapy
was also started as inpatients in cases 5, 7, and
14, whereas in case 9 it had been started only as
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Table 5.  Voriconazole Administration Before Addition of Sirolimus
Case No. of Days Before Concurrent No. of Days of
No. Voriconazole Dosage Coadministration Sirolimus Oral Dosage Drugsb Coadministration
1 200 mg i.v. q12h ≥ 7a 1 mg/day None 1
2 200 mg p.o. q12h ≥ 1a 12 mg x 1 day, then None 7
2 mg/day
3 300 mg p.o. q12h ≥ 1a 1 mg/day x 2 days, then None 4
0.5 mg/day x 2 days
7 200 mg p.o. q12h ≥ 4a 1 mg/day x 4 days, then None 11
1 mg 3 times/wk x 7 days
8 200 mg i.v. q12h, then ≥ 3a 4 mg x 1 day, then skipped (A) Rifampin, 9
changed to p.o. on day 2 1 day, then 3 mg x 1 day, phenytoin,
of coadministration then 1 mg x 1 day omeprazole
14 150 mg i.v. q12h x 3 doses, 7 0.5 mg/day (B, D) Phenytoin 9
then 200 mg i.v. q12h
20 200 mg p.o. q12h ≥ 7a 6 mg x 1 day, then 2 mg/day None 8
x 4 days, 4 mg x 1 day,
then 3 mg/day x 2 days
R = random; T = trough; A = after coadministration; B = before coadministration; D = during coadministration.
aNumber of days the patient received voriconazole as documented on the medication administration record as an inpatient before sirolimus was
started; however, the patient may have been taking voriconazole as an outpatient before admission.
bCytochrome P450 3A isoenzyme or P-glycoprotein inducer or inhibitor.
cSirolimus trough concentrations were defined as plasma concentrations obtained within 3 hrs before the next scheduled dose or within 1 hr
after the next scheduled dose if the scheduled dose was not administered at the correct time (e.g., if nursing staff waited until the trough was
obtained before administration of the next sirolimus dose).
dNumber of hours after start of coadministration that sirolimus concentration was obtained.
eDose decreased to 0.5 mg/day 24 hrs before sirolimus concentration was obtained.
fDose decreased to 1 mg 3 times/wk 48 hrs after sirolimus concentration was obtained.
Figure 3. Case 21 is an example of the minimal effect of
voriconazole (Vori) administration on plasma sirolimus
(Siro) concentrations in a patient already receiving a potent
inhibitor of cytochrome P450 3A4 isoenzymes (itraconazole).
Time 0 is 168 hours before coadministration of sirolimus
and voriconazole.
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an outpatient.  In case 5, the patient received the
combination for approximately 1 year (the
patient was admitted 5 times during a 1-yr
period); sirolimus concentrations were success-
fully maintained at less than 20 ng/ml (mean
sirolimus concentration of 7.8 ± 1.8; range
3.6–9.4 ng/ml) throughout this period with a
regimen of oral sirolimus 1 mg/day and
voriconazole 200 mg every 12 hrs.
Concurrent Use of Cytochrome P450 3A
Isoenzyme or P-glycoprotein Inducers or
Inhibitors
In 2 cases, the patients were concurrently
receiving a CYP3A isoenzyme inducer before and
during coadministration of voriconazole and
sirolimus (Tables 5 and 6).  In no cases did the
patients receive a concomitant P-glycoprotein
inducer, but in 9 cases the patients received a P-
glycoprotein inhibitor (itraconazole, cyclosporine,
or omeprazole10, 24) during coadministration.
Adverse Effects of Combination Therapy
Adverse effects potentially attributable to
elevated sirolimus concentrations (> 20 ng/ml)
occurred in 2 (8%) of 25 cases; sirolimus
concentrations were not available in 6 cases.  In
case 2, the patient developed thrombocytopenia
with no other identifiable causes.  In case 8, the
patient developed renal dysfunction requiring
hemodialysis and leukopenia, although tacrolimus
may have contributed to these toxicities; however,
the patient’s tacrolimus concentrations were
within normal limits (4–6.7 ng/ml).
The 30-day mortality rate after the last day of
combination therapy as an inpatient was 30% (7
of 23 patients).  Six (86%) of these seven patients
were not receiving combination therapy at the
time of death.  The causes of death were infec-
tious complications in three patients and trans-
plant complications in four patients.
Discussion
Although the voriconazole prescribing infor-
mation states that its use with sirolimus is
contraindicated,9 clinicians have been faced with
the challenge of still needing to use the two
agents together.  Despite a lack of prospective,
randomized, controlled studies evaluating the
concurrent use of voriconazole and sirolimus in
the transplant population, several published case
reports describe the concomitant use of these two
agents.  In one case report, in which a patient
received sirolimus 1 mg/day while receiving
voriconazole, the area under the plasma concen-
tration–time curve of sirolimus increased by 4.5-
fold during concurrent administration with
voriconazole; on discontinuation of voriconazole,
the sirolimus dose had to be increased to 3
mg/day to maintain therapeutic sirolimus concen-
trations.17 This report also described increased
sirolimus concentrations when voriconazole was
administered concomitantly in two other
transplant recipients.  The sirolimus concentration
increased by 2.5-fold when a patient, who had
been stabilized with sirolimus 4 mg/day, began to
receive voriconazole despite a slow taper of the
sirolimus dose to 1 mg/day.  The other patient
had been maintained with sirolimus 1.5 mg/day
(concentrations ranged from 17–19 ng/ml before
the addition of voriconazole), and the concen-
tration (sirolimus was continued at 1.5 mg/day)
increased to 29 ng/ml 2 weeks after the addition
of voriconazole.
A second case report noted that in two patients
treated with voriconazole and sirolimus concur-
rently, the sirolimus dose had to be decreased by
75–87.5% in order to maintain therapeutic trough
concentrations of sirolimus.18 A case series
reviewed 11 patients who received the two agents
together for a median of 33 days (range 3–100
days).16 In the 8 patients whose sirolimus dose
was decreased by 90% after the addition of
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Table 5.  (continued)
Time Sirolimus
Concen-
Sirolimus tration
Concentration Obtained
(ng/ml)c (hrs)d Comments
10.2 (R) 71 Discharged with combination
therapy
24.9 (R) 21 Sirolimus doses held and dosed
by concentration; voriconazole
later discontinued
8.3e (T) 63 Discharged with combination
therapy
5.4f (R) 32 Discharged with combination
therapy
36.0 (R) 6 Sirolimus dosed by concentration
then discontinued
3.4 (R) 40 Discharged with combination
therapy
15.1 (R) 13 Voriconazole changed to
micafungin; discharged with
sirolimus
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voriconazole, no toxicity was observed, and
sirolimus trough concentrations remained within
3–12 ng/ml, the target trough range in that study.
The three patients who did not have their
sirolimus doses reduced when voriconazole was
added had sirolimus trough concentrations above
the upper limit of the target trough range; however,
it was not reported whether these patients were
also receiving other CYP3A isoenzyme inhibitors
during that time.
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Table 6.  Sirolimus Administration Before Addition of Voriconazole
Sirolimus Time Sirolimus
Concentration Concentration
Oral Before Obtained Before Sirolimus Dosage
Case Sirolimus No. of Days Before Coadministration Coadministration Adjustment During
No. Dosage Coadministration (ng/ml) (hrs) Voriconazole Dosage Coadministration
4 1 mg q.d. ≥ 1a 4.0e 384 300 mg p.o. x 1, then ↓ to 0.5 mg q.d.
200 mg p.o. q12h
x 2 doses, then
400 mg i.v. q12h 
5 1 mg q.d.f ≥ 2a 11.0e 99 200 mg p.o. q12h ↓ 0.5 mg q.d. 2 days
before voriconazole
added
6 6 mg q.d. ≥ 1a 12.5 68 420 mg i.v. q12h No
x 2 doses
10 1 mg q.d. ≥ 7a 3.7 14 200 mg p.o. q12h ↓ to 1 mg q.o.d.
x 5 days, then ↑ to
1.5 mg q.d. x 5 days,
then ↓ 1 mg q.d.
x 4 days, then ↓ to
1 mg q.o.d. x 6 days
12 2 mg x 1 day, ≥ 6a 17.6 112g 450 mg i.v. x 1 dose ↓ to 2 mg q.d.
then 4 mg q.d.
x 5 days
15 2 mg x 1 day, 6 13.2 20 175 mg i.v. q12 h No
then 1 mg q.d. x 2 doses
(missed 1 dose)
17 1 mg q.d. x ≥ 7a 3.4e 101 200 mg p.o. q12h ↑ to 2 mg q.d. x 3
5 days, then days, then ↓ to
1.5 mg q.d.j 0.5 mg q.d.
18 2 mg q.d. x ≥ 7a 8.2k 176 600 mg i.v. q12h ↓ to 1 mg q.d.
5 days x 3 doses x 2 days before
voriconazole added
21 1 mg q12h x ≥ 7a 30.8 2 200 mg p.o. q.d. Changed to 1 mg q.d.
2 days, then 1 day before adding
0.5 mg q12h x voriconazole
4 days
22 1 mg q.d. ≥ 1a 9.8 21 200 mg p.o. q12h ↑ to 3 mg x 1 dose,
then 1 mg q12h
R = random; T = trough; B = before coadministration; D = during coadministration; A = after coadministration.
aNumber of days the patient received sirolimus as documented on the medication administration record as an inpatient before voriconazole was
started; however, the patient may have been taking sirolimus as an outpatient before admission.
bCytochrome P450 3A isoenzyme or P-glycoprotein inducer or inhibitor. 
cSirolimus trough concentrations were defined as plasma concentrations obtained within 3 hrs before the next scheduled dose or within 1 hr
after the next scheduled dose if the scheduled dose was not administered at the correct time (e.g., if nursing staff waited until the trough was
obtained before administration of the next sirolimus dose).
dNumber of hours after start of coadministration that sirolimus concentration was obtained.
eReflects sirolimus 1-mg/day dosing.
fSirolimus 1 mg/day according to admission note; no doses given for first 2 days of admission, then restarted at 0.5 mg/day.
gSirolimus concentration that was obtained 24 hrs after dose increased from 2 to 4 mg/day. 
h44 hrs after voriconazole was discontinued.
i0.5 hrs after sirolimus was given.
jNo sirolimus dose given x 1 day before increasing sirolimus dose to 1.5 mg/day.
kReflects sirolimus 2-mg/day dosing.
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To coadminister these two agents safely,
consideration must be given to which agent
(sirolimus or voriconazole) the patient is
receiving first, the dosage of sirolimus, the
sirolimus concentration before the addition of
voriconazole if the patient is already receiving
sirolimus, and concurrent CYP3A isoenzyme
inhibitors or inducers.  As illustrated by our
cases 2 and 8 and the drug interaction study in
healthy subjects reported in the voriconazole
package insert,9 large loading doses of sirolimus
are generally not necessary in patients who have
been receiving voriconazole before the addition
of sirolimus.  The CYP3A isoenzyme activity of
patients receiving voriconazole will be inhibited
already, and thus, they will have lower amounts
of active enzyme to metabolize sirolimus.  As
illustrated in cases 1, 3, 7, and 14, these patients
should begin to receive sirolimus at lower doses
(0.5–1 mg/day) and sirolimus concentrations
should be monitored closely.
In patients receiving sirolimus before the
addition of voriconazole, the management
strategy should be based on the daily dose of
sirolimus, the sirolimus concentration before
addition of voriconazole, and whether the patient
has been receiving other CYP3A isoenzyme
inhibitors.  Patients stabilized with low doses of
sirolimus (0.5–2 mg/day) and with prevoriconazole
sirolimus concentrations of 12 ng/ml or lower
may need only a 50% decrease in their sirolimus
dose before addition of voriconazole, as demon-
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Table 6.  (continued)
Sirolimus
Concentration Time Sirolimus
After Start of Concentration
No. of Days of Coadministration Obtained
Concomitant Drugsb Coadministration (ng/ml)c (hrs)d Comments
None 1 12.4 (R) 8 Sirolimus discontinued
(B, D) Itraconazole 2 7.2 (R) 141 Discharged with combination
therapy
None 1 32.7 (R) 26 Voriconazole discontinued
(A) Fluconazole 20 2.8 (R) 33 Sirolimus concentration ranged
from 2.8–18 ng/ml during
20 days of coadministration
(B, D) Phenobarbital 2 27.6 (R) 56h Sirolimus continued,
(B, D, A) Cyclosporine voriconazole changed to
(A) Fluconazole fluconazole, voriconazole
changed to fluconazole
(B, D, A) Cyclosporine 2 13.2 (R) 0.5i Sirolimus continued,
(B, D) Fluconazole voriconazole changed to
caspofungin
None 5 3.8 (R) 44 Sirolimus discontinued,
discharged with voriconazole
(A) Omeprazole 2 7.4 (R) 41 Sirolimus and voriconazole
(1 dose) discontinued
(B, D, A) Itraconazole 1 39.6 (R) 15 Patient received itraconazole
(A) Cyclosporine during entire admission,
discharged with voriconazole
(D, A) Cyclosporine 4 10.4 (T) 12.5 Sirolimus discontinued,
discharged with voriconazole
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strated by cases 4, 5, 10, and 18.  These patients
may have lower baseline amounts of CYP3A
isoenzymes; thus, the addition of a CYP3A
isoenzyme inhibitor may not have as dramatic an
effect as that in patients who have higher
amounts of CYP3A isoenzymes at baseline.
In contrast, based on previous literature and
cases 6 and 12 in our series, patients receiving
high sirolimus doses (≥ 4 mg/day) who have
prevoriconazole sirolimus concentrations of 12
ng/ml or higher, should undergo a preemptive
sirolimus dosage adjustment of approximately
70–90% after addition of voriconazole.10–12 These
patients may have higher amounts of baseline
CYP3A isoenzymes (perhaps due to the presence
of CYP3A inducers, such as rifampin, phenytoin,
or phenobarbital) and thus need higher doses of
sirolimus to reach target sirolimus concentrations.
Inhibition of CYP3A isoenzymes in these patients
may cause a significant decrease in the amount of
active CYP3A isoenzymes, inhibiting the
metabolism of sirolimus and resulting in
significant elevations in sirolimus concentrations.
Patients receiving other CYP3A isoenzyme
inhibitors concurrently with sirolimus, as in case
21 who had been receiving itraconazole, may
only need minor sirolimus dosage adjustments
with the addition of or change to another CYP3A
isoenzyme inhibitor.  Adding another CYP3A
isoenzyme inhibitor or changing to another agent
with a similar degree of CYP3A isoenzyme
inhibition will likely cause very little change in
CYP3A isoenzyme activity because the patient’s
enzyme activity may be maximally inhibited by
the first inhibitor.
It is important for clinicians to remember that
the duration of enzyme inhibition produced (and
thus the effect on substrate concentrations) may
be quite prolonged, in particular if both the
substrate and the inhibitor have long half-lives.
This can be readily observed in case 6 (Figure 2),
where administration of only two doses of
voriconazole resulted in prolonged inhibition of
sirolimus.
Nevertheless, sirolimus concentrations should
be monitored routinely during coadministration
with voriconazole and when any other CYP3A
isoenzyme inhibitors are added to or deleted
from the patient’s drug regimen, as not all
interactions are predictable.  For example, the
patient in case 20, who had been receiving
voriconazole, did not experience as elevated a
sirolimus concentration as expected after
administration of a loading dose of sirolimus of 6
mg; the measured concentration was 15.1 ng/ml
after coadministration.  The patients in cases 17
and 22 had to have their sirolimus doses
increased, despite the addition of voriconazole, to
maintain therapeutic sirolimus concentrations.
These patients may not have been fully absorbing
the voriconazole or sirolimus (case 17 had
GVHD of the gastrointestinal tract, case 20 had
been receiving total parenteral nutrition, and case
22 had cystic fibrosis) or may have had altered
voriconazole metabolism (as described below).
Case 15 had a sirolimus concentration of 13.2
ng/ml before and after the addition of
voriconazole.  The postvoriconazole concentration
was obtained 0.5 hour after the dose of sirolimus
was given; thus, the patient may not have fully
absorbed the sirolimus as the time to peak
sirolimus absorption is 1–2 hours, and this
patient also had GVHD of the gastrointestinal
tract.
Plasma voriconazole concentrations are unpre-
dictable due to inconsistent absorption and
genetic polymorphisms in CYP2C19, the
isoenzyme primarily responsible for voriconazole’s
metabolism.  Variations in plasma voriconazole
concentrations may in turn affect its degree of
CYP3A isoenzyme inhibition, resulting in
inconsistencies in sirolimus concentrations.
Furthermore, whether sirolimus, a weak CYP3A
isoenzyme inhibitor, affects voriconazole concen-
trations is not known.  Voriconazole concentrations
were not monitored in our study patients.
However, we recognize that measuring voriconazole
concentrations would be helpful in future studies
assessing the drug interaction between these two
agents.
Several limitations must be considered when
evaluating this study.  As it is a retrospective
study based on medical record reviews, we could
only report data that had been documented in the
patients’ medical records, and we did not have
access to patients’ outpatient medical records.
Although we collected data on other CYP3A
isoenzymes and P-glycoprotein inhibitors and
inducers that the patients received, we were not
able to fully characterize the cumulative effects of
these inhibitors and inducers on sirolimus
concentrations.  Target sirolimus concentrations
range depending on what type of transplantation
the patient receives, the other immunosuppressive
agents the patient is receiving concurrently, and
how much time has elapsed since the transplan-
tation.  The use of other ranges would affect the
need for and amount of dosage adjustments.  The
average turnaround time for sirolimus concen-
trations at our institution is 1–2 days.  Other
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hospitals may have to send patient samples to
another institution for analysis, resulting in a
turnaround time of more than 1 week, hindering
therapeutic drug monitoring of sirolimus.
Finally, the study was limited in terms of the
number of patients receiving voriconazole and
sirolimus concurrently.  Nevertheless, the
number of patients in our study is far greater
than has been previously reported in the
literature.
Conclusion
We evaluated 31 cases (in 23 patients) of
voriconazole and sirolimus coadministration.
There were only 2 cases in which adverse effects
occurred, possibly attributable to elevated
sirolimus concentrations.  Based on the results of
this study and previous literature, the drug
interaction between voriconazole and sirolimus is
clinically manageable despite the significant
CYP3A isoenzyme drug interaction with the
potential for elevated sirolimus concentrations.
Based on the results of this pilot study, a protocol
on the management of the combination of
sirolimus and voriconazole will be implemented
and prospectively evaluated for efficacy and
safety.
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